ARTV

insider transactions

Artiva Biotherapeutics, Inc. — buys & sells by directors, officers and 10% owners (SEC Form 4).

30D 90D 1Y

Cluster buy signal: 2 different insiders made open-market purchases in the last 90 days, totalling $128.7M.

Net shares · 90d

+11.6M

11.7M buy · 53.0K sell

Net value · 90d

$128.3M

$128.7M in · $477.8K out

Sentiment · 90d

Net buying

100% buying · 0% selling

Open-market trades · 90d

11.7M buy · 53.0K sell

Net buy / sell volume

Tap or hover the chart for daily net volume. Green = net buying, red = net selling.

All transactions

Buy·P
Jun 16, 26

RA CAPITAL MANAGEMENT, L.P. / RA Capital Healthcare Fund LP / RA Capital Nexus Fund, L.P. / RA Capital Nexus Fund III, L.P. / Peter Kolchinsky / Rajeev M. Shah

Director, 10% Owner

$1.1M

124.9K sh · $8.89

Own +1%
Buy·P
Jun 15, 26

RA CAPITAL MANAGEMENT, L.P. / RA Capital Healthcare Fund LP / RA Capital Nexus Fund, L.P. / RA Capital Nexus Fund III, L.P. / Peter Kolchinsky / Rajeev M. Shah

Director, 10% Owner

$138.6K

15.4K sh · $8.99

Own +0%
Buy·P
Jun 12, 26

RA CAPITAL MANAGEMENT, L.P. / RA Capital Healthcare Fund LP / RA Capital Nexus Fund, L.P. / RA Capital Nexus Fund III, L.P. / Peter Kolchinsky / Rajeev M. Shah

Director, 10% Owner

$3.4M

391.0K sh · $8.57

Own +2%
Buy·P
Jun 11, 26

RA CAPITAL MANAGEMENT, L.P. / RA Capital Healthcare Fund LP / RA Capital Nexus Fund, L.P. / RA Capital Nexus Fund III, L.P. / Peter Kolchinsky / Rajeev M. Shah

Director, 10% Owner

$4.3M

548.6K sh · $7.91

Own +3%
Buy·P
Jun 10, 26

RA CAPITAL MANAGEMENT, L.P. / RA Capital Healthcare Fund LP / RA Capital Nexus Fund, L.P. / RA Capital Nexus Fund III, L.P. / Peter Kolchinsky / Rajeev M. Shah

Director, 10% Owner

$721

103 sh · $7.00

Own +0%
Buy·P
Jun 9, 26

RA CAPITAL MANAGEMENT, L.P. / RA Capital Healthcare Fund LP / RA Capital Nexus Fund, L.P. / RA Capital Nexus Fund III, L.P. / Peter Kolchinsky / Rajeev M. Shah

Director, 10% Owner

$3.3M

479.0K sh · $6.91

Own +3%
Sell·S
May 19, 26

Heather Raymon

SVP, Research and Development

$27.9K

3.1K sh · $9.01

Own -2%
Sell·S
May 19, 26

Christopher Horan

Chief Tech Operations Officer

$63.1K

7.0K sh · $9.01

Own -2%
Sell·S
May 19, 26

Jennifer Bush

COO, CLO, Compliance Officer

$79.2K

8.8K sh · $9.01

Own -3%
Sell·S
May 19, 26

Subhashis Banerjee

Chief Medical Officer

$63.4K

7.0K sh · $9.01

Own -5%
Sell·S
May 19, 26

Fred Aslan KEY

Chief Executive Officer

$244.3K

27.1K sh · $9.01

Own -2%
Grant·A
May 18, 26

Gines Diego Miralles KEY

President & Head of R&D

$0

232.5K sh

Own New
Grant·A
May 18, 26

Gines Diego Miralles KEY

President & Head of R&D

$0

77.5K sh

Own New
Buy·P
May 11, 26

RA CAPITAL MANAGEMENT, L.P. / RA Capital Healthcare Fund LP / RA Capital Nexus Fund, L.P. / RA Capital Nexus Fund III, L.P. / Peter Kolchinsky / Rajeev M. Shah

Director, 10% Owner

$25.0M

2.2M sh · $11.52

Own New
Buy·P
May 11, 26

RA CAPITAL MANAGEMENT, L.P. / RA Capital Healthcare Fund LP / RA Capital Nexus Fund, L.P. / RA Capital Nexus Fund III, L.P. / Peter Kolchinsky / Rajeev M. Shah

Director, 10% Owner

$75.0M

6.5M sh · $11.52

Own +75%
Buy·P
May 11, 26

GC Corp. / GC Cell Corp

10% Owner

$4.0M

347.2K sh · $11.52

Own +28%
Buy·P
May 11, 26

GC Corp. / GC Cell Corp

10% Owner

$12.5M

1.1M sh · $11.52

Own +33%

Date▾	Insider	Role	Type	Shares	Own Δ	Price	Value
Jun 16, 2026	RA CAPITAL MANAGEMENT, L.P. / RA Capital Healthcare Fund LP / RA Capital Nexus Fund, L.P. / RA Capital Nexus Fund III, L.P. / Peter Kolchinsky / Rajeev M. Shah	Director, 10% Owner	Buy P	124.9K	+1%	$8.89	$1.1M
Jun 15, 2026	RA CAPITAL MANAGEMENT, L.P. / RA Capital Healthcare Fund LP / RA Capital Nexus Fund, L.P. / RA Capital Nexus Fund III, L.P. / Peter Kolchinsky / Rajeev M. Shah	Director, 10% Owner	Buy P	15.4K	+0%	$8.99	$138.6K
Jun 12, 2026	RA CAPITAL MANAGEMENT, L.P. / RA Capital Healthcare Fund LP / RA Capital Nexus Fund, L.P. / RA Capital Nexus Fund III, L.P. / Peter Kolchinsky / Rajeev M. Shah	Director, 10% Owner	Buy P	391.0K	+2%	$8.57	$3.4M
Jun 11, 2026	RA CAPITAL MANAGEMENT, L.P. / RA Capital Healthcare Fund LP / RA Capital Nexus Fund, L.P. / RA Capital Nexus Fund III, L.P. / Peter Kolchinsky / Rajeev M. Shah	Director, 10% Owner	Buy P	548.6K	+3%	$7.91	$4.3M
Jun 10, 2026	RA CAPITAL MANAGEMENT, L.P. / RA Capital Healthcare Fund LP / RA Capital Nexus Fund, L.P. / RA Capital Nexus Fund III, L.P. / Peter Kolchinsky / Rajeev M. Shah	Director, 10% Owner	Buy P	103	+0%	$7.00	$721
Jun 9, 2026	RA CAPITAL MANAGEMENT, L.P. / RA Capital Healthcare Fund LP / RA Capital Nexus Fund, L.P. / RA Capital Nexus Fund III, L.P. / Peter Kolchinsky / Rajeev M. Shah	Director, 10% Owner	Buy P	479.0K	+3%	$6.91	$3.3M
May 19, 2026	Heather Raymon	SVP, Research and Development	Sell S	3.1K	-2%	$9.01	$27.9K
May 19, 2026	Christopher Horan	Chief Tech Operations Officer	Sell S	7.0K	-2%	$9.01	$63.1K
May 19, 2026	Jennifer Bush	COO, CLO, Compliance Officer	Sell S	8.8K	-3%	$9.01	$79.2K
May 19, 2026	Subhashis Banerjee	Chief Medical Officer	Sell S	7.0K	-5%	$9.01	$63.4K
May 19, 2026	Fred Aslan KEY	Chief Executive Officer	Sell S	27.1K	-2%	$9.01	$244.3K
May 18, 2026	Gines Diego Miralles KEY	President & Head of R&D	Grant A	232.5K	New	—	$0
May 18, 2026	Gines Diego Miralles KEY	President & Head of R&D	Grant A	77.5K	New	—	$0
May 11, 2026	RA CAPITAL MANAGEMENT, L.P. / RA Capital Healthcare Fund LP / RA Capital Nexus Fund, L.P. / RA Capital Nexus Fund III, L.P. / Peter Kolchinsky / Rajeev M. Shah	Director, 10% Owner	Buy P	2.2M	New	$11.52	$25.0M
May 11, 2026	RA CAPITAL MANAGEMENT, L.P. / RA Capital Healthcare Fund LP / RA Capital Nexus Fund, L.P. / RA Capital Nexus Fund III, L.P. / Peter Kolchinsky / Rajeev M. Shah	Director, 10% Owner	Buy P	6.5M	+75%	$11.52	$75.0M
May 11, 2026	GC Corp. / GC Cell Corp	10% Owner	Buy P	347.2K	+28%	$11.52	$4.0M
May 11, 2026	GC Corp. / GC Cell Corp	10% Owner	Buy P	1.1M	+33%	$11.52	$12.5M

About ARTV insider trading

This page tracks insider transactions for Artiva Biotherapeutics, Inc. (ARTV) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.